LCN2 and acute kidney injury: For the first time, we evaluated cell-cycle arrest biomarkers, analyzed by a commercial point-of-care kit, the Nephrocheck, head to head with urinary NGAL, and urinary cystatin C, in general ICU patients at risk of AKI.